These findings align with literature proposing multiple pathways through which semaglutide may act, mitigating vascular stiffening, adverse lipid profiles, inflammation, and endothelial dysfunction, alongside effects on glycemic control, insulin resistance, and weight loss [1, 4]
Additional safety considerations include: Acute pancreatitis risk : Patients should be monitored for severe abdominal pain Gallbladder disease : Including cholelithiasis and cholecystitis Dehydration and acute kidney injury : Particularly with gastrointestinal side effects Hypoglycemia : When used with insulin or sulfonylureas in patients with diabetes Diabetic retinopathy complications : Particularly with semaglutide in patients with pre-existing retinopathy Patients with hypothyroidism should undergo thyroid function monitoring when starting weight loss injections
Vials commonly come in 1 mg, 2 mg, 5 mg, 10 mg, or 15 mg
This can lead to weight reduction that lasts over time
Contraindications (Who Should NOT Take It) Your safety is our priority
Tirzepatide provided 47% greater relative weight loss compared to semaglutide